THE DOSE
your daily dose of Innovative, trending, and groundbreaking stories from across the cosmos.
Welcome to the SykoActive Studios Daily-Dose
Dive into the latest breakthroughs and transformative trends at the intersection of psychedelics, cannabis, and AI-driven research. Embrace the cutting-edge developments reshaping our understanding and approach to mental and spiritual health.
Atai's Strategic Move: Investing in Beckley Psytech for Rapid-Acting Psychedelic Medicines
In an unprecedented move, Atai Life Sciences, a global biotech company, has invested a significant amount in Beckley Psytech, a company specializing in psychedelic medicine. This strategic investment marks a monumental step towards the development of rapid-acting psychedelic medicines, signifying a potential paradigm shift in mental health treatment.
Adult ADHD Doctors on TikTok
If you have ADHD or know someone who does, you may have encountered some of the myths that surround this condition. In this blog post, we will debunk some of the common misconceptions about ADHD and provide you with some facts that are backed by science and reliable sources.
Psychedelic drugs can reveal what your purpose truly is
Psychedelic drugs are substances that can alter perception, mood, and cognition, often producing profound and sometimes mystical experiences. Many people who use psychedelics report that they feel a sense of meaning, purpose, and connection with themselves, others, and the universe. But what is psychedelic meaning and how does it arise in the brain?
Genetic Testing: A New Era in Depression Treatment
New insights into the neural mechanisms of depression and brain stimulation and pave the way for future applications in other neuropsychiatric disorders.
Unraveling the Mysteries of the Mind: Bruce Lipton’s Research on Epigenetics and Neuroplasticity
This article delves into the groundbreaking research of Dr. Bruce Lipton on the Human Genome, Epigenetics, and the transformative power of Neuroplasticity Therapy. We explore how these scientific advancements are revolutionizing our understanding of stress, diseases, and the potential of Hypnotherapy.
Deja Vu: Mystery of memory
Deja vu is the strange feeling that a novel situation is familiar. This paper reviews the scientific literature on deja vu, including proposed explanations, prevalence, associated factors, and implications. Research suggests deja vu occurs in 60-100% of healthy individuals, but the exact mechanisms remain unclear. Leading hypotheses propose deja vu results from divided attention, fatigue, anxiety, or abnormalities in memory formation and retrieval.
The Dangers of Fentanyl: A Synthetic Opioid Causing Thousands of Overdose Deaths
The Dangers of Fentanyl: A Synthetic Opioid Causing Thousands of Overdose Deaths
The Therapeutic Potential of Psilocybin: A Study on Rats Reveals Promising Results
A new study conducted on rats has provided further insights into the effects of repeated low doses of psilocybin, revealing not only its safety profile but also its potential in enhancing resilience to stress.
The Mystical World of Energy Healing: A Deep Dive
In the vast realm of holistic health, energy healing emerges as a beacon of hope for many seeking alternative methods to achieve wellness. It's a journey into the unseen, where the tangible meets the intangible, and where the rhythm of our very essence is tuned to its optimal frequency.
🌐🚀global news update🗞️ | October 1-10, 2023
The first week of October 2023 has been a rollercoaster of advancements and challenges across various sectors globally. From strides in mental health support to exciting AI innovations, the psychedelic and cannabis sphere, scientific discoveries, space explorations, and societal matters, we’ve seen it all. Here’s a detailed breakdown of the major happenings.
Impact of the Pandemic on Behavioral Health Diagnosis and Treatment: Key Trends Shaping the Health Economy
The COVID-19 pandemic has had a profound impact on the behavioral health landscape in America. This article explores the key trends that have emerged in behavioral health diagnosis and treatment, highlighting the changes in supply, demand, and yield. Drawing insights from a data-driven report, it sheds light on the challenges faced by different population groups and geographies. The goal is to provide stakeholders with a foundation for understanding and addressing the evolving behavioral health crisis.
Ketamine Shows Promise as a Treatment for Various Mental Health Conditions
A recent study conducted by researchers from the University of British Columbia Okanagan and the University of Exeter has shed light on the potential of ketamine in treating a range of mental health disorders, including depression, PTSD, bipolar disorder, and eating disorders. By analyzing over 150 global studies on sub-anesthetic doses of ketamine, the researchers discovered significant anti-depressant and anti-suicidal properties. This breakthrough could pave the way for innovative and more effective mental health treatments.
Ibogaine research is being conducted to address the opioid epidemic
In an unprecedented move against the opioid epidemic, Kentucky has launched a groundbreaking $42 million program to probe the potential of ibogaine. This naturally-occurring psychedelic has shown considerable promise in reducing dependency on opioids.
Psychedelic Therapies Included In Your Employee Benefits
Enthea, a provider of psychedelic healthcare insurance plans, declared that it will expand its services into 40 markets across the US in 2023 with the goal of making workplace benefits for psychedelic-assisted therapies reasonable, equitable, and available.
Elon Musk Promotes The Use Of Psychedelic Hallucinogens For Mental Health
'We Should Take This Seriously”
Elon Musk, Owner of Tesla, SpaceX, Boring Co. Starlink and Solar City, is the world’s richest man and outspoken eccentric innovator of “The Future”, who believes we need to ditch the pills and look at Psychedelics, Hallucinogens, and Entheogens like Mushrooms, LSD, and MDMA as a Serious Treatment for Mental Health and Expanding Human Consciousness.
Psychedelic BioTech Company Treats Gambling Disorder with Ketamine
Awakn Life Sciences Corp. , a psychedelic biotechnology company focused on researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder, has announced on June 2nd that they have initiated a larger behavioral addiction study investigating ketamine as a treatment for Gambling Disorder.
Activists Arrested At DEA Headquarters Amid Protest Over Psychedelics
Activists staged a demonstration outside of the Drug Enforcement Administration headquarters in Virginia, demanding that the agency allow terminally ill patients to access psilocybin therapy. The Protest was meant to call attention to DEA’s obstruction of Right to Try statutes at the federal and state level that patients and advocates say should facilitate legal use of psychedelics.
Mushrooms Are Magic For Depression Relief
For the first time we find that psilocybin works differently from conventional antidepressants – making the brain more flexible and fluid, and less entrenched in the negative thinking patterns associated with depression
TripSitter Plans Virtual Mental Health Clinics
TripSitter Clinic Corp is an international psychedelic medicine and telehealth company enabling physician directed safe and legal entheogen treatment plans. They are currently developing virtual health clinics to help with monitoring, and coaching with patients and licensed physicians. They have recently teamed up in medical, clinical, and administrative operations with Insight Systems, PBC dba Reconscious Medical, which is a psychedelic psychotherapy company engaging in both in-clinic and online virtual care with safety, monitoring, and support provided through a proprietary technology platform.